Health

Origin Agritech GMO Corn Hybrid is the One and Only Triple Stack Trait Corn Selected for National Demo Plot, Being Grown There in Anticipation of 2023 Commercial Launch

BEIJING, April 11, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), announced today that its GMO corn hybrid is the one and only triple stacked trait corn selected for the national demo plot and is currently being grown there in anticipation of a 2023 commerci...

2023-04-11 20:45 1860

OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023

NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...

2023-04-11 20:00 1461

SK Biopharmaceuticals Wins Red Dot Design Award for Wearable Devices

* 'Zero WiredTM' and 'Zero EarbudsTM' named 'Winners' in the healthcare category for outstanding product design * SK Biopharmaceuticals' wearable devices earn a global accolade once again following the CES® Innovation Awards SEOUL, South Korea, April 10, 2023 /PRNewswire/ -- SK Biopharmaceuti...

2023-04-11 08:00 1874

Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"

SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...

2023-04-10 20:18 2124

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

YONGIN, South Korea, April 9, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Radiation Oncology Journal,which demonstrates the feasibility of cell-free DNA(cfDNA) monitoring to predict treatment response and detect min...

2023-04-10 11:39 1590

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...

2023-04-07 16:34 4388

Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")

SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...

2023-04-07 10:00 2156

AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering

NEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...

2023-04-07 07:15 4471

Wondercise to announce the new face of signature Live Motion Matching™ technology at FIBO 2023: a revolutionary fitness experience with wearables and live content

Groundbreaking motion tracking technology provides users with prime training content and real-time performance feedback * Wondercise will launch its newest release on the award-winning Live Motion Matching™ technology at FIBO 2023 with live demonstrations on site. * Patented fitness technolog...

2023-04-06 22:30 3055

GC Cell Obtains Anti-bribery Management System Certification

* Obtained ISO 37001 from Korea Compliance Initiative (KCI) * To practice ESG management by enhancing management transparency and ethical management YONGIN, South Korea, April 6, 2023 /PRNewswire/ -- GC Cell (KOSDAQ: 144510), a Korean biotech company, announced onApr. 6th that it has successf...

2023-04-06 18:03 2076

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ), announced today it has entered into a collaboration agreement wi...

2023-04-06 10:20 2387

BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer

CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ --  BIORCHESTRA , a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) leveraging the Biorchestra Drug Delivery System (BDDSTM), w...

2023-04-05 20:00 2323

Standigm and Institut Pasteur Korea Identify Lead Compounds for Resistant Tuberculosis Thanks to Right Foundation Grant

Research achievements enabled by a combination of advanced AI platforms, research capabilities, and drug discovery technologies SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discov...

2023-04-05 00:07 2403

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration toinitiate a Phase 2 clinical trial of BS...

2023-04-04 20:50 1922

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 20:00 2845

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids * The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworld.com...

2023-04-04 10:33 2181

AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.

NEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform foc...

2023-04-03 21:00 2949

GC Cell and New Management Embarking on a New Chapter

* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...

2023-04-03 16:47 2192

Timekettle AI Translator Earbuds Empower International Medical Workers

SHENZHEN, China, April 3, 2023 /PRNewswire/ -- Technology company, Timekettle, recently sponsored the 13th Global Implantology Week organized by the ZimVie Association atNew York University. The four-day event brought together medical experts from over 30 countries to share their knowledge and ex...

2023-04-03 16:17 1724

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncolo...

2023-04-03 15:10 3601
1 ... 104105106107108109110 ... 280